Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Pancreatic Cancer Resectable × avelumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 27 Carcinoma, Transitional Cell 25 Urinary Bladder Neoplasms 23 Neoplasms 20 Carcinoma, Merkel Cell 20 Carcinoma, Renal Cell 18 Neoplasm Metastasis 17 Breast Neoplasms 15 Colorectal Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 12 Ovarian Neoplasms 12 Triple Negative Breast Neoplasms 8 Head and Neck Neoplasms 8 Pancreatic Neoplasms 7 Stomach Neoplasms 6 Melanoma 6 Recurrence 5 Prostatic Neoplasms 5 Carcinoma, Hepatocellular 5 Ureteral Neoplasms 4 Small Cell Lung Carcinoma 4 Neuroendocrine Tumors 4 Carcinoma, Squamous Cell 4 Uterine Cervical Neoplasms 3 Urethral Neoplasms 3 Skin Neoplasms 3 Sarcoma 3 Lymphoma 3 Leukemia, Myeloid, Acute 3 Kidney Neoplasms 3

Interventions

Gemcitabine 4 130-nm albumin-bound paclitaxel 2 sintilimab 1 nimotuzumab 1 avelumab 1 Taxes 1 Oxaliplatin 1 Leucovorin 1 Irinotecan 1 Hydroxychloroquine 1 Fluorouracil 1 Capecitabine 1 Antineoplastic Agents 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03344172 2020-05-14

17-134

University of Pittsburgh

Phase 2 Terminated

32 enrolled 14 charts

Gastrointestinal

Pancreatic Cancer Resectable

Data powered by HemOnc (CC BY 4.0) Colophon ⚡